Login / Signup

Avatar acceptability: views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions.

Laura K FawcettClaire E WakefieldSheila SivamPeter Gordon MiddletonPeter A B WarkJohn WidgerAdam JaffeShafagh A Waters
Published in: ERJ open research (2021)
These findings indicate acceptance of patient-derived organoids as a tool to predict treatment response by the majority of people surveyed. This may indicate successful future implementation into healthcare systems.
Keyphrases
  • healthcare
  • cystic fibrosis
  • primary care
  • pseudomonas aeruginosa
  • current status
  • lung function
  • quality improvement
  • combination therapy
  • replacement therapy
  • air pollution
  • smoking cessation